Insight Molecular Diagnostics Inc (IMDX)

NASD · Healthcare · Diagnostics & Research · USA

Insight Molecular Diagnostics Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.

Insight Molecular Diagnostics develops molecular diagnostic test kits for transplant organ rejection monitoring and oncology. The company operates a CLIA-certified laboratory in Tennessee and serves hospitals, transplant centers, and research institutions through laboratory tests and in-house kitted products. Its GraftAssure family of assays measures donor-derived cell-free DNA and includes a Medicare-reimbursed laboratory test and research kits.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Insight Molecular Diagnostics Inc stock.

Our verdict on IMDX

Not valued: We cannot value this company yet.

We do not publish a value for this company: not even its current assets cover what it owes.

ETFs with the most weight in IMDX

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than IMDX in Diagnostics & Research

23 more in this industry show a wider margin of safety.

Is IMDX undervalued or overvalued?

We do not publish a verdict on IMDX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of IMDX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.